Q2 2026 analysis shows expanding approvals, stronger uptake, and a shift toward evidence-driven biosimilar evaluation
The submission is backed by positive results from the Phase 3 AFFIRM study
The approval was driven by data from the Phase III TULIP-SC trial
The trial also demonstrated significant improvements across multiple secondary endpoints
The trial will enroll up to 42 patients in Finland across four cohorts
Sodium Phosphates Injection is indicated as a source of phosphorus, for addition to large volume intravenous fluids, to prevent or correct hypophosphatemia in patients with restricted or no oral intake
Bocunebart works by blocking pituitary adenylate cyclase-activating polypeptide
The PRIOH-1 study met its primary endpoint, delivering statistically significant and clinically meaningful improvements in lesion healing
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
